Publikationen in Zusammenarbeit mit Forschern von Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (20)

2024

  1. Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism

    Frontiers in Endocrinology, Vol. 15

  2. Epicardial and liver fat implications in albuminuria: a retrospective study

    Cardiovascular Diabetology, Vol. 23, Núm. 1

  3. Impact of primary aldosteronism on kidney function: Results from the SPAIN-ALDO registry

    Journal of Hypertension, Vol. 42, Núm. 10, pp. 1805-1812

  4. Is adrenal venous sampling always necessary to differentiate between unilateral and bilateral primary aldosteronism? Lesson from the SPAIN-ALDO register

    Endocrine, Vol. 84, Núm. 2, pp. 683-693

  5. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry

    High Blood Pressure and Cardiovascular Prevention, Vol. 31, Núm. 1, pp. 43-53

2023

  1. Autonomous cortisol secretion in patients with primary aldosteronism: prevalence and implications on cardiometabolic profile and on surgical outcomes

    Endocrine Connections, Vol. 12, Núm. 9

  2. Effect of Obesity on Clinical Characteristics of Primary Aldosteronism Patients at Diagnosis and Postsurgical Response

    The Journal of clinical endocrinology and metabolism, Vol. 109, Núm. 1, pp. e379-e388

  3. Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function

    Molecular Metabolism, Vol. 75

  4. Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism

    Cell Metabolism, Vol. 35, Núm. 9, pp. 1630-1645.e5

2022

  1. Adrenal venous sampling in primary aldosteronism: Experience of a Spanish multicentric study (Results from the SPAIN-ALDO Register)

    Endocrine, Vol. 78, Núm. 2, pp. 363-372

  2. Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease

    Frontiers in Medicine, Vol. 9

  3. Differences in the presentation and evolution of primary aldosteronism in elderly (≥65 years) and young patients (<65 years)

    Endocrine Connections, Vol. 11, Núm. 6

  4. Predictive model of hypertension resolution after adrenalectomy in primary aldosteronism: the SPAIN-ALDO score

    Journal of Hypertension, Vol. 40, Núm. 12, pp. 2486-2493

  5. Transient elastography and serum markers of liver fibrosis associate with epicardial adipose tissue and coronary artery calcium in NAFLD

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. O-GlcNAcylated p53 in the liver modulates hepatic glucose production

    Nature Communications, Vol. 12, Núm. 1

  3. Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points

    Journal of Hepatology

2020

  1. Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD

    FASEB Journal, Vol. 34, Núm. 9, pp. 11816-11837

  2. Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: How to manage in clinical practice

    Polish Archives of Internal Medicine, Vol. 130, Núm. 11, pp. 975-985

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145